Mechanism of "Ephedrae Herba-Descurainiae Semen Lepidii Semen" combination in treatment of bronchial asthma based on network pharmacology and experimental verification.
10.19540/j.cnki.cjcmm.20220211.403
- Author:
Bei-Bei ZHANG
1
;
Meng-Nan ZENG
2
;
Qin-Qin ZHANG
1
;
Ru WANG
1
;
Ju-Fang JIA
1
;
Peng-Li GUO
1
;
Meng LIU
1
;
Wei-Sheng FENG
2
;
Xiao-Ke ZHENG
2
Author Information
1. School of Pharmacy,Henan University of Chinese Medicine Zhengzhou 450046,China Engineering and Technology Center for Chinese Medicine Development of Henan Province Zhengzhou 450046,China.
2. School of Pharmacy,Henan University of Chinese Medicine Zhengzhou 450046,China Engineering and Technology Center for Chinese Medicine Development of Henan Province Zhengzhou 450046,China Collaborative Innovation Center for Chinese Medicine and Respiratory Diseases Co-constructed by Henan Province and Education Ministry of P.R.China,Henan University of Chinese Medicine Zhengzhou 450046,China.
- Publication Type:Journal Article
- Keywords:
Descurainiae Semen Lepidii Semen;
Ephedrae Herba;
bronchial asthma;
network pharmacology
- MeSH:
Animals;
Asthma/drug therapy*;
Cyclin D1;
Dexamethasone/adverse effects*;
Drug Combinations;
Drugs, Chinese Herbal/therapeutic use*;
Eosine Yellowish-(YS)/adverse effects*;
Ephedra;
ErbB Receptors;
Hematoxylin/therapeutic use*;
Interleukin-10;
Interleukin-6;
Mitogen-Activated Protein Kinase 8/therapeutic use*;
Molecular Docking Simulation;
Network Pharmacology;
Ovalbumin/adverse effects*;
Periodic Acid/adverse effects*;
Phosphatidylinositol 3-Kinases;
Proto-Oncogene Proteins c-akt/metabolism*;
Quercetin;
RNA, Messenger;
Rats
- From:
China Journal of Chinese Materia Medica
2022;47(18):4996-5007
- CountryChina
- Language:Chinese
-
Abstract:
This study aims to investigate mechanism of "Ephedrae Herba-Descurainiae Semen Lepidii Semen" combination(MT) in the treatment of bronchial asthma based on network pharmacology and in vivo experiment, which is expected to lay a theoretical basis for clinical application of the combination. First, the potential targets of MT in the treatment of bronchial asthma were predicted based on network pharmacology, and the "Chinese medicine-active component-target-pathway-disease" network was constructed, followed by Gene Oncology(GO) term enrichment and Kyoto Encyclopedia of Genes and Genomes(KEGG) pathway enrichment of the potential targets. Molecular docking was used to determine the binding activity of key candidate active components to hub genes. Ovalbumin(OVA, intraperitoneal injection for sensitization and nebulization for excitation) was used to induce bronchial asthma in rats. Rats were classified into control group(CON), model group(M), dexamethasone group(DEX, 0.075 mg·kg~(-1)), and MT(1∶1.5) group. Hematoxylin and eosin(HE), Masson, and periodic acid-Schiff(PAS) staining were performed to observe the effect of MT on pathological changes of lungs and trachea and goblet cell proliferation in asthma rats. The levels of transforming growth factor(TGF)-β1, interleukin(IL)6, and IL10 in rat serum were detected by enzyme-linked immunosorbent assay(ELISA), and the mRNA and protein levels of mitogen-activated protein kinase 8(MAPK8), cyclin D1(CCND1), IL6, epidermal growth factor receptor(EGFR), phosphatidylinositol 3-kinase(PI3 K), and protein kinase B(Akt) by qRT-PCR and Western blot. Network pharmacology predicted that MAPK8, CCND1, IL6, and EGFR were the potential targets of MT in the treatment of asthma, which may be related to PI3 K/Akt signaling pathway. Quercetin and β-sitosterol in MT acted on a lot of targets related to asthma, and molecular docking results showed that quercetin and β-sitosterol had strong binding activity to MAPK, PI3 K, and Akt. In vivo experiment showed that MT could effectively alleviate the symptoms of OVA-induced asthma rats, improve the pathological changes of lung tissue, reduce the production of goblet cells, inhibit the inflammatory response of asthma rats, suppress the expression of MAPK8, CCND1, IL6, and EGFR, and regulate the PI3 K/Akt signaling pathway. Therefore, MT may relieve the symptoms and inhibit inflammation of asthma rats by regulating the PI3 K/Akt signaling pathway, and quercetin and β-sitosterol are the candidate active components.
